Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Immunotec Signs up Green Cross Medical Science to Market T-Cell SARS-CoV-2 Kit in South Korea

NEW YORK ─ Oxford Immunotec said on Monday that it has entered into a memorandum of understanding with Green Cross Medical Science (GCMS) and Mesdia to market its research-use-only T-SPOT Discovery SARS-CoV-2 kit in South Korea.

Under the agreement, GCMS will market and sell the kit, Mesdia will import it, and Oxford Immunotec Korea will provide overall support.

Financial and other terms of the agreement were not disclosed.

T-SPOT Discovery SARS-CoV-2 adds a research test for measuring the T cell response to SARS-CoV-2 infection to GCMS' portfolio, which already consists of six diagnostic tests for COVID-19.

"This MOU means that the T-SPOT Discovery SARS-CoV-2 kit will be available to more researchers and multiple biopharmaceutical companies that are developing innovative treatments and vaccines across South Korea, which we believe will make a significant contribution towards informing how we can better manage the ongoing pandemic in the country," Walt Ling, VP commercial APAC for Oxford Immunotec, said in a statement.

The T-Spot Discovery SARS-CoV-2 kit, based on the Oxford, UK-based firm's T-Spot technology, is already available for research use in Europe and the US. The test is being used in studies in the UK for COVID-19 vaccine development and for clinical evaluation, the firm said.

Study data recently released by Public Health England using the kit suggests that individuals with a SARS-CoV-2-specific T cell response, but without detectible antibodies, may be protected from infection, Oxford Immunotec said. As a result, the T-cell response to SARS-CoV-2 may be an important adjunct to serological analysis, it added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.